Zydus Lifesciences Q1 Review: A Mixed Bag for Investors

Zydus Lifesciences Ltd. has announced its Q1 FY26 results, with revenues of Rs 65,737 million, which were in-line with estimates. However, Ebitda (Rs 20,885 million) and Net earnings (Rs 14,668 million) were below expectations.

Revenue Growth: A Positive Note

Revenue was up 7% YoY and 3% QoQ, led by the International Formulations business, which saw a 37% YoY growth. The India formulations business grew 8% YoY, while US formulations grew by 3% YoY (flat in $ terms). This growth is a positive note for investors, as it indicates that the company is performing well in its core business areas.

North America Revenue: A Significant Contributor

North America revenue now stands at 49% of the total revenue for Zydus Lifescience. The contribution from gMirabegron and gRevlimid remains disproportionately high in overall earnings. This is a significant factor for investors to consider, as the performance of these products will have a major impact on the company’s overall financials.

Risks and Challenges Ahead

In case new high-value launches (which are usually unpredictable) do not fructify, there is a substantial risk of earnings decline in FY27. gMirabegron contribution continuity in FY27 hinges on the court outcome (Q4 FY26). This is a significant risk factor that investors need to consider, as it could impact the company’s future earnings.

Target Price Revision

We revise our estimates as we incorporate Amplitude Surgicals in our model for FY26 and beyond. Our revised target price stands at Rs 1,020, based on 25x FY27 EPS, and we retain a Hold on the stock. This revision is based on the company’s current performance and future growth prospects.

Investor Takeaway

Overall, Zydus Lifesciences Q1 results are a mixed bag for investors. While the revenue growth is a positive note, the below-expectation Ebitda and Net earnings are a cause for concern. The significant contribution from North America revenue and the risks associated with new product launches are also important factors to consider. Investors should keep a close eye on the company’s future performance and adjust their investment strategies accordingly.

For more information on Zydus Lifesciences and other pharmaceutical companies, visit our website. We provide in-depth analysis and updates on the Indian stock market, helping you make informed investment decisions.